Literature DB >> 11553566

Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.

S Pal1, I Theodor, E M Peterson, L M de la Maza.   

Abstract

Infertility, ectopic pregnancy, and chronic abdominal pain are frequent complications of genital infections with Chlamydia trachomatis. In an attempt to produce a vaccine to protect against this pathogen we purified and refolded the C. trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP). This preparation, mixed with Freund's adjuvant using vortexing or sonication, was used to immunize BALB/c mice that were subsequently challenged in the upper genital tract. Vaginal cultures were taken on a weekly basis, and mice were mated 6 weeks after the challenge. Gels of the vortexed MOMP showed a predominant band with a molecular size of 62 kDa and weaker bands at 42 and 132 kDa, while the sonicated MOMP had a single band with a molecular size of 42 kDa. Following immunization with these two preparations, strong humoral and cell-mediated immune responses were detected in the mice inoculated with the vortexed MOMP. On the other hand, mice immunized with the sonicated MOMP had a strong humoral immune response but a relatively weak cell-mediated immune response, as determined by a T-cell lymphoproliferative assay and level of cytokine production by splenocytes. Vaginal cultures showed that the mice immunized with the vortexed MOMP were significantly protected, as determined by a decrease in the number of animals with positive cultures, the length of time the mice shed viable organisms, and the number of inclusion-forming units recovered per mouse. Animals immunized with the sonicated MOMP, on the other hand, showed a weaker level of protection based on the same three parameters. After mating, the number of fertile animals and number of embryos per mouse were significantly higher for the mice immunized with vortexed MOMP, but not for the mice immunized with sonicated MOMP, compared to those of the control groups. In conclusion, immunization with a purified and refolded preparation of the C. trachomatis MoPn MOMP confers a significant level of protection in mice against a genital challenge.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11553566      PMCID: PMC98757          DOI: 10.1128/IAI.69.10.6240-6247.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein.

Authors:  M Tuffrey; F Alexander; W Conlan; C Woods; M Ward
Journal:  J Gen Microbiol       Date:  1992-08

2.  Susceptibility of mice to vaginal infection with Chlamydia trachomatis mouse pneumonitis is dependent on the age of the animal.

Authors:  S Pal; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 3.  Chlamydia trachomatis: a major threat to reproduction.

Authors:  J Paavonen; P Wølner-Hanssen
Journal:  Hum Reprod       Date:  1989-02       Impact factor: 6.918

4.  Interactions between the gonadal steroids and the immune system.

Authors:  C J Grossman
Journal:  Science       Date:  1985-01-18       Impact factor: 47.728

5.  Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines.

Authors:  K H Ramsey; R G Rank
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

6.  Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility.

Authors:  L M de la Maza; S Pal; A Khamesipour; E M Peterson
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection.

Authors:  J A Whittum-Hudson; L L An; W M Saltzman; R A Prendergast; A B MacDonald
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

8.  Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000.

Authors:  A E Washington; P Katz
Journal:  JAMA       Date:  1991-11-13       Impact factor: 56.272

9.  A new animal model for the study of Chlamydia trachomatis genital infections: infection of mice with the agent of mouse pneumonitis.

Authors:  A L Barron; H J White; R G Rank; B L Soloff; E B Moses
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

10.  Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.

Authors:  L Weström; R Joesoef; G Reynolds; A Hagdu; S E Thompson
Journal:  Sex Transm Dis       Date:  1992 Jul-Aug       Impact factor: 2.830

View more
  53 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

Review 2.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

3.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

4.  Induction of immune memory by a multisubunit chlamydial vaccine.

Authors:  F O Eko; E Ekong; Q He; C M Black; J U Igietseme
Journal:  Vaccine       Date:  2010-12-22       Impact factor: 3.641

5.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

6.  Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumonitis major outer membrane protein.

Authors:  Sukumar Pal; Jose Bravo; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

7.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

8.  Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge.

Authors:  Nina Dieu Nhien Tran Nguyen; Anja W Olsen; Emma Lorenzen; Peter Andersen; Malene Hvid; Frank Follmann; Jes Dietrich
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

9.  Serovar-specific immune responses to peptides of variable regions of Chlamydia trachomatis major outer membrane protein in serovar D-infected women.

Authors:  Pragya Srivastava; Rishein Gupta; Hem Chandra Jha; Rajneesh Jha; Apurb Rashmi Bhengraj; Sudha Salhan; Aruna Mittal
Journal:  Clin Exp Med       Date:  2008-09-25       Impact factor: 3.984

10.  Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.

Authors:  Anja Weinreich Olsen; Michael Theisen; Dennis Christensen; Frank Follmann; Peter Andersen
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.